Tempest CFO granted 140,000 stock options
Tempest Therapeutics, Inc. reported that Chief Financial Officer Nicholas Maestas received a grant of employee stock options covering 140,000 shares of common stock at an exercise price of $1.64 per share.
Rhea-AI Filing Summary
Tempest Therapeutics, Inc. reported that Chief Financial Officer Nicholas Maestas received a grant of employee stock options covering 140,000 shares of common stock at an exercise price of $1.64 per share. These options expire on March 30, 2036 and are held as a direct ownership position.
According to the vesting terms, 25% of the total shares will vest on March 31, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on Maestas’s continued service. Following this grant, he holds 140,000 options in this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 140,000 shares
Grant/Award
1 txn
Insider
Maestas Nicholas
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 140,000 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 140,000 contracts (Direct)
Footnotes (1)
- F1. This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.
Key Figures
Options granted: 140,000 options
Exercise price: $1.64 per share
Underlying shares: 140,000 shares
+4 more
7 metrics
Options granted
140,000 options
Employee stock option award to CFO Nicholas Maestas
Exercise price
$1.64 per share
Strike price for underlying common stock
Underlying shares
140,000 shares
Common stock underlying the option grant
Grant date
March 31, 2026
Transaction date of the option award
Expiration date
March 30, 2036
Option term end date
Initial vesting
25% on March 31, 2027
Cliff vesting of first portion of options
Remaining vesting period
36 monthly installments
Post-cliff vesting schedule, subject to continued service
Key Terms
Employee Stock Option (right to buy), exercise price, vesting, expiration date, +1 more
5 terms
Employee Stock Option (right to buy) financial
"security_title: "Employee Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "1.6400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This option shall vest with respect to 25% of the total number of shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-03-30T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
FAQ
What insider transaction did Tempest Therapeutics (TPST) report for Nicholas Maestas?
Tempest Therapeutics reported a grant of employee stock options to CFO Nicholas Maestas for 140,000 shares of common stock. The options are compensation-related, not an open-market purchase or sale, and provide the right to buy shares at a fixed exercise price.
What is the exercise price of the new TPST stock options granted to the CFO?
The options granted to Tempest Therapeutics’ CFO have an exercise price of $1.64 per share. This is the price at which he can buy the company’s common stock under the award, regardless of future market price movements, once the options vest.
How do the TPST stock options granted to the CFO vest over time?
The stock options vest gradually based on continued service. Twenty-five percent of the 140,000 underlying shares vest on March 31, 2027, and the remaining shares vest in 36 equal monthly installments after that date, creating a four-year vesting horizon from the initial cliff vesting.
When do the newly granted Tempest Therapeutics (TPST) options to the CFO expire?
The options granted to the CFO expire on March 30, 2036. After this expiration date, any unexercised portion of the 140,000-share option award can no longer be used to purchase Tempest Therapeutics common stock at the $1.64 exercise price.
Is the TPST Form 4 transaction a stock sale or purchase by the CFO?
The Form 4 transaction is an award of employee stock options, classified as an acquisition, not a market trade. It reflects a compensation grant giving the CFO the right to buy 140,000 shares at $1.64, rather than a direct buy or sell on the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
